Artificial Vital Organs And Medical Bionics Market (2026 - 2033)

Artificial Vital Organs And Medical Bionics Market Summary

The global artificial vital organs and medical bionics market size was valued at USD 45.0 billion in 2025 and is projected to grow from USD 49.2 billion in 2026 to USD 91.7 billion in 2033, at a CAGR of 9.3% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 44.5% in 2025. Market growth has been driven by several factors, including technological advancements, the rising incidence of disorders, and an aging population. Moreover, increased investment in research and development, as well as the growing number of patients waiting for organ transplants, have contributed to the market’s growth. Furthermore, government efforts to ensure patient safety have also stimulated market growth.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Market growth worldwide is driven by a confluence of demographic shifts and technological advancements. The increasing number of individuals over the age of 65, who are more susceptible to organ failure, is a major factor driving demand for organ implants and artificial vital organs. According to the Directorate General of Health Services, India alone has over 1.8 lakh people suffering from renal failure, with only 60,000 receiving transplants, while over 2 lakh people suffer from liver failure or cancer, with only 1,500 transplants performed. As the global population ages, the need for effective solutions to address organ failure has become more pressing, creating opportunities for market players to develop innovative products.

Continuous technological breakthroughs in medical research and biomedical engineering are also contributing to market expansion. The shortage of donor organs for transplantation, which results in lengthy waiting times and limited availability of suitable donors, has created a high demand for artificial vital organs. Furthermore, the rising prevalence of chronic diseases, such as heart disease, diabetes, and kidney disease, which often result in organ failure, is another significant factor contributing to market growth.

Growing healthcare expenditure, particularly in emerging economies, is another driver for market growth. As patients seek to improve their quality of life and extend their lifespan, the adoption of artificial vital organs and medical bionics is increasing. Moreover, positive government actions to protect patient safety standards and research activities, as well as increased awareness of public and private reimbursement coverage, are boosting adoption rates and creating opportunities for market players.

Analyst Perspective

The market is experiencing steady growth, driven by a rising incidence of chronic diseases, increasing demand for organ transplants, and the adoption of life-prolonging treatments. Artificial organs and medical bionics are increasingly incorporated into cardiac care, neurodegenerative disease management, and chronic disease management. As demand for high-precision and advanced medical technologies continues to rise, companies that focus on product innovation, technological enhancement, and application diversification will be well positioned to capitalize on long-term growth opportunities.

Artificial Organ Insights

The heart segment dominated the market, accounting for approximately 57.5% of revenue in 2025. This increase is happening due to an increase in the incidence of chronic diseases, scarcity of hearts for transplant, and advancement of the operations and potent, effective drugs and treatment. Advances in the transplantation of artificial organs and bionic devices, such as artificial hearts, livers, and eyes, are increasing due to improved biological compatibility, safety, and lifespan, thereby improving patients' lives. For instance, in March 2025, BiVACOR, a clinical-stage medical device company, announced the successful implantation of its BiVACOR Total Artificial Heart (TAH). The implantation occurred in November 2024. Following weeks of in-hospital monitoring, the patient was the first in the world to be discharged from the hospital with the BiVACOR TAH as he awaited a heart transplant. After having the device for 105 days, a donor heart became available, and the patient received a heart transplant on March 6, 2025.

The pancreas segment is expected to experience the fastest growth with a CAGR of approximately 10.5% over the forecast period. The primary driver for this is an increase in the number of diabetic patients. Furthermore, Advancements in technology, improvements in surgical procedures, and impressive surgical success rates are driving the expansion of the pancreas transplant market during the forecast period. Pancreas transplant recipients are experiencing improved outcomes and quality of life. Better survival outcomes and other long-term impacts of pancreas transplants have contributed to the patient’s awareness of the benefits of the procedure.

Bionic Insights

Brain bionics dominated the market, accounting for approximately 35.0% of revenue in 2025. Increased prevalence of neurological conditions such as Parkinson’s disease, depression, and epilepsy is driving market growth. Moreover, advancements in technology regarding neural implants, neuroprosthetics, and improvements in treatments help patients with new hope and quality of life; with this, more patients are getting diagnosed with the treatment. For instance, in September 2025, Case Western Reserve University developed a technology to restore a sense of touch, making a prosthetic hand feel like a part of one’s own body rather than artificial and disconnected. The neuroprosthesis, called “iSens” (Implanted Somatosensory Electrical Neurostimulation and Sensing system), uses electrodes implanted in the arm to detect muscle movement, control the hand, and stimulate nerves, thereby sending touch sensations from the prosthesis's fingertips to the brain. An implanted neural control device communicates between the electrodes and the prosthesis through Bluetooth. 

Exoskeleton bionics are expected to register the fastest growth over the forecast period with a CAGR of approximately 10.5%. Exoskeletons are more often applied in the context of rehabilitation from strokes, spinal cord injuries, or other neurological disorders, enhancing movement and motor skills. Moreover, the rapidly aging population is increasing demand for exoskeletons, as older adults require assistance with mobility. Apart from healthcare, exoskeleton technology is being used in construction, logistics, and manufacturing to prevent work-related accidents and improve worker performance. The cases of spinal cord injuries that cause paralysis further boost the bionic exoskeleton market as they result in permanent disabilities.

Regional Insights

North America artificial vital organs and medical bionics market dominated the global market with a revenue share of approximately 44.5% in 2025. This growth can be attributed to different factors, together with technological development, an increase in investment in the development of artificial organs and bionic systems, positive assistance from the government and private bodies, and an upward push in the variety of patients who are geared up for analysis. For instance, in October 2025, HistoSonics, Inc., the developer of the Edison Histotripsy System and novel histotripsy therapy platform, announced the closing of a USD 250 million financing led by its new ownership group and included additional investors Thiel Bio and Founders Fund, among others. The financing will support the ongoing commercial expansion of HistoSonics’ Edison System into new global markets, accelerate the development of new clinical indications throughout the body, and strengthen operational capacity for the next phase of growth.

To learn more about this report, Download Free Sample Report

U.S. Artificial Vital Organs and Medical Bionics Market Trends

The artificial vital organs and medical bionics market in the U.S. dominated North America with a revenue share of approximately 72.0% in 2025 and is expected to grow during the forecast period due to a well-established healthcare infrastructure and high demand for advanced medical technologies such as artificial vital organs and medical bionics.

Europe Artificial Vital Organs And Medical Bionics Market Trends

The artificial vital organs and medical bionics market in Europe was identified as a lucrative region in this industry. Increasing healthcare awareness, enhanced healthcare infrastructure, and rapid technological advancements are among the factors driving market growth. In addition, the increasing adoption of artificial organs, advanced technology, and improved healthcare infrastructure is likely to drive market growth.

The UK artificial vital organs And medical bionics market has a significant market share. The shortage of organ donors and the high demand for vital artificial organs are driving market growth. There is a growing trend in the UK towards implantable medical bionics, which offer more permanent solutions than external devices.

The artificial vital organs And medical bionics market in Germany is expected to grow during the forecast period due to the rising prevalence of chronic diseases requiring organ replacement and bionic implants. With the growth of the geriatric population, the rise in chronic diseases is a common result of market growth.

Asia Pacific Artificial Vital Organs And Medical Bionics Market Trends

The artificial vital organs and medical bionics market in the Asia Pacific is expected to experience the fastest growth during the forecast period, with a CAGR of over 11.0%. Due to rising disposable income, improved healthcare infrastructure, and increased awareness, the marketplace is expected to grow during the forecast period. Countries in the Asia Pacific region have large populations, including many people with chronic diseases, which may pressure market growth.

China artificial vital organs And medical bionics market is expected to grow in the forecast period due to a rise in chronic diseases that lead to organ failure and an increase in the geriatric population, driving the market growth. Due to rapid urbanization, people tend towards unhealthy diets and consumption of alcohol, which results in organ failure and drives the growth of the market.

The artificial vital organs and medical bionics market in India is expected to grow significantly during the forecast period. This growth can be attributed to the aging population, increased road accidents, and advances in technology.

Key Artificial Vital Organs And Medical Bionics Company Insights

The market is characterized by multiple players, including established brands, startups, and specialty companies, with major players focusing on developing advanced artificial organs and medical bionics through ongoing research and innovation. Some key companies in the market include Medtronic, Inc., LifeNet Health, Terumo Corporation, Ekso Bionics Holdings, Inc., Nano Retina Ltd., and Edwards Lifesciences Corporation.

• Medtronic designs, develops, manufactures, and markets medical devices and solutions. The products and services are intended to address several cardiovascular diseases and conditions, including vascular diseases, heart failure, neurological disorders, and spinal and musculoskeletal disorders. Moreover, it offers biologic products for the orthopedic and dental industries and is a giant in pacemaker manufacturing.
• Edwards Lifesciences Corporation is involved in the research, production, and sales of equipment used in structural heart, critical care, and surgical monitoring. In addition, the company provides transcatheter heart valve repair and replacement products for treating mitral and tricuspid valve diseases.

Key Artificial Vital Organs And Medical Bionics Companies

The following key companies have been profiled for this study on the artificial vital organs and medical bionics market:

• Medtronic, Inc.

• LifeNet Health

• Terumo Corporation

• Ekso Bionics Holdings, Inc.

• Nano Retina Ltd.

• Edwards Lifesciences Corporation

• InnoScot Health Ltd.

• Ottobock SE & Co. KGaA

• Orthofix Medical Inc.

Recent Developments

• In October 2025, OrganOx Ltd. announced the completion of its acquisition by Terumo Corporation. The acquisition will enable investment in research and development, including advancing the OrganOx metra platform technology beyond liver transplantation. It will also enable the company to capitalize on opportunities to expand the use of normothermic machine perfusion (NMP) for organ support and enhancement.

• In December 2025, Nephrodite, Inc., a medical device company developing an implantable, continuous renal replacement system, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company’s Holly implantable, continuous dialysis system. Current treatment options, including hemodialysis and peritoneal dialysis, limit mobility and patients’ quality of life, and no more effective alternatives have become available since the advent of hemodialysis more than 70 years ago.

Global Artificial Vital Organs and Medical Bionics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global artificial vital organs and medical bionics market report based on artificial organs, bionics, and region:

• Artificial Organs Outlook (Revenue, USD Billion, 2021 - 2033)

  • Heart

  • Kidney

  • Liver

  • Pancreas

  • Lungs

• Bionics Outlook (Revenue, USD Billion, 2021 - 2033)

  • Ear Bionics

  • Vision Bionics

  • Exoskeletons

  • Bionic Limbs

  • Brain Bionics

  • Cardiac Bionics

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait